Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653302 | 0.90 | SMN1; SMN2 (0.49) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL20223143 | 0.82 | SMN1; SMN2 (0.44) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL17344113 | 0.82 | CA12 (0.48) | KDM4EALDH1A1MAPTPKMHSD17B10 | |
| SCHEMBL24186174 | 0.82 | ALOX15 (0.47) | KDM4EALDH1A1MAPTMAPK1ATM | |
| SCHEMBL24092263 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1MAPTPKMHPGD | |
| SCHEMBL17130071 | 0.81 | MAPT (0.46) | KDM4EALDH1A1MAPTPKMHSD17B10 | |
| SCHEMBL3403855 | 0.81 | NQO2 (0.47) | KDM4EALDH1A1MAPTPKMHSD17B10 | |
| SCHEMBL22557059 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1MAPTPKMHSD17B10 | |
| SCHEMBL16232800 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1MAPTPKMHSD17B10 | |
| SCHEMBL16232808 | 0.81 | KMT2A (0.46) | KDM4EALDH1A1MAPTPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10276808-B2 | Organic electroluminescent compound and organic electroluminescent device comprising the same | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2019-04-30 | — | — | US | disclosed |
| WO-2019068961-A1 | NOVEL POLYMERS, METHODS FOR PREPARING SAME, AND USES THEREOF PARTICULARLY FOR METAL CAPTURE | UNIVERSITE PARIS-SUD (FR) | 2019-04-11 | — | — | WO | disclosed |
| WO-2017103545-A1 | LANTHANIDE COMPLEXES FOR CRYSTALLISING BIOLOGICAL MACROMOLECULES AND DETERMINING THE CRYSTALLOGRAPHIC STRUCTURE THEREOF | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2017-06-22 | — | — | WO | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2238135-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | KDM4E 4652/4885ALDH1A1 1221/4885MAPT 3217/4885 |
| US-10276808-B2 | Organic electroluminescent compound and organic electroluminescent device comprising the same | OR10J3, EPCAM, TYR | KDM4E 950/4885ALDH1A1 213/4885MAPT 1755/4885 |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | KDM4E 322/4885ALDH1A1 866/4885MAPT 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.